David Zhang, PH.D., MBA

Abivax

David is Chief Strategy Officer at Abivax, responsible for Regulatory Affairs, Quality Assurance, Biometrics and Health Economic and Outcome Research. Prior to joining Abivax, David was Senior Vice President, Head of Biometrics and Data Management at Alumis. As part of the founding management team at Alumis, he served as Chief Information Officer responsible for building up capabilities in Biometrics, IT, Facilities and Investor Relations during the early days of the company. Before joining Alumis, David was Vice President of biometrics, data science and digital health at MyoKardia where he built the advanced analytics capabilities from the ground up to enable the successful completion of critical phase 3 study design, data readouts and New Drug Application submission of Mavacamten (CAMZYOS) until its acquisition by Bristol Myers Squibb in 2020. Prior to MyoKardia, David spent 15 years at Roche/Genentech with increasing responsibilities leading and building biostatistics and strategic innovation functions. He began his pharmaceutical industry career at Eli Lilly and Abbott Laboratories after receiving his Ph.D. in biostatistics with a minor in genetics from UCLA and completing post-doctoral research at Columbia University. In addition to his day job, David serves on the Advisory Council of BBSW, an organization he was a founding member of and served as its President in 2022.